2025 H2 -tulosraportti
78 päivää sitten
‧38 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 058 | - | - | ||
| 1 | - | - | ||
| 12 | - | - | ||
| 14 | - | - | ||
| 570 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sittenQube increases short https://investorprat.com/TRMED/short
·3 t sittenexplains the significance of Qube's short in Thor Medical. With today's closing price of 4,43 kr, 0,8 % short corresponds to only around 2,9 million shares or approx. 13 million kroner. For a fund with enormous sums under management, this is in practice a very small position — approximately 0,003 % of a capital base of 380 billion NOK. I therefore believe this looks much more like regular algorithm/quant trading than a large fundamental bet against Thor Medical. Small and volatile biotech companies often automatically end up in such models due to liquidity, volatility, and issuance history. In my opinion, the size of the short at least does not indicate any strong conviction that the case will fail.
·1 päivä sittenThis is a stock for those with nerves of steel and a long-term perspective. During the recently held Mineral Days, the proximity and connection to Fensfeltet at Ulefoss (3.5 mil away) was emphasized as a strength for a long-term collaboration. Read the article here: https://www.linkedin.com/posts/thor-medical-asa_radioligandtherapy-nuclearmedicine-precisionmedicine-activity-7460210978530594816-w90h?utm_source=share&utm_medium=member_ios&rcm=ACoAAAcE6pMBR73kbdP4i1PKMH6bpO8f-HYw9-8- 1 päivä sitten1 päivä sitten·1 päivä sittenAnna Karmann from AdvanCell gave a very interesting presentation at the UCSF-UCLA PSMA conference about something that may have been underestimated in radioligand therapy: dose optimization. Her main point was that today's approved RLT treatments like Lutathera and Pluvicto were developed extremely quickly, but without dose, treatment interval, and treatment duration being thoroughly optimized first. AdvanCell has therefore built dose optimization directly into the development of 212Pb-ADVC001, their lead-212-based PSMA alpha-therapy. The most interesting from the Phase 1 data: - The most intensive dosing regimens yielded the fastest and deepest PSA responses. - No dose-limiting toxicities were observed. - No dose reductions or severe delayed radiation side effects so far. - Denser treatment can potentially counteract resistance and "repopulation" of cancer cells between doses. AdvanCell therefore believes that future radioligand therapy perhaps should resemble more modern cancer treatment in general: 1. Hard induction phase for rapid tumor control 2. Then maintenance treatment to keep the disease down with lower burden They also use extensive PET/SPECT imaging and dosimetry to optimize the treatment.
16 t sitten16 t sittenAdvanCell + Alpha-1 = first fully scalable Pb-212 treatment chain. Benefits for AdvanCell: • ✔ Isotope shortage eliminated • ✔ Dose intensity increases → better efficacy • ✔ FDA approval accelerated by 1–2 years • ✔ Phase 2 may be sufficient for approval • ✔ Indications may expand • ✔ Company value increases significantly New approval window for AdvanCell: 👉 2028–2030 (previously 2029–2031) 
·2 päivää sittenDidn't see THAT coming!Poistettu·2 päivää sittenPoistettu·2 päivää sittenShorts trying their luck? They have increased somewhat lately and know that it can quickly go a bit sideways until after summer, just a thought. If one thinks long-term, just close Nordnet and open in autumn/possibly next year, then I believe one will be more than well in profit here. If one, however, is after quick money and trading, then this feels a bit dead now, at least until summer/August, but I can absolutely be wrong here. It just seems like we need some news, and even if everything is going smoothly, most is probably anticipated first after summer. But to put it in the drawer for half a year, probably absolutely fantastic. Only hope and belief, of course.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H2 -tulosraportti
78 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenQube increases short https://investorprat.com/TRMED/short·3 t sittenexplains the significance of Qube's short in Thor Medical. With today's closing price of 4,43 kr, 0,8 % short corresponds to only around 2,9 million shares or approx. 13 million kroner. For a fund with enormous sums under management, this is in practice a very small position — approximately 0,003 % of a capital base of 380 billion NOK. I therefore believe this looks much more like regular algorithm/quant trading than a large fundamental bet against Thor Medical. Small and volatile biotech companies often automatically end up in such models due to liquidity, volatility, and issuance history. In my opinion, the size of the short at least does not indicate any strong conviction that the case will fail.
- ·1 päivä sittenThis is a stock for those with nerves of steel and a long-term perspective. During the recently held Mineral Days, the proximity and connection to Fensfeltet at Ulefoss (3.5 mil away) was emphasized as a strength for a long-term collaboration. Read the article here: https://www.linkedin.com/posts/thor-medical-asa_radioligandtherapy-nuclearmedicine-precisionmedicine-activity-7460210978530594816-w90h?utm_source=share&utm_medium=member_ios&rcm=ACoAAAcE6pMBR73kbdP4i1PKMH6bpO8f-HYw9-8
- 1 päivä sitten1 päivä sitten·1 päivä sittenAnna Karmann from AdvanCell gave a very interesting presentation at the UCSF-UCLA PSMA conference about something that may have been underestimated in radioligand therapy: dose optimization. Her main point was that today's approved RLT treatments like Lutathera and Pluvicto were developed extremely quickly, but without dose, treatment interval, and treatment duration being thoroughly optimized first. AdvanCell has therefore built dose optimization directly into the development of 212Pb-ADVC001, their lead-212-based PSMA alpha-therapy. The most interesting from the Phase 1 data: - The most intensive dosing regimens yielded the fastest and deepest PSA responses. - No dose-limiting toxicities were observed. - No dose reductions or severe delayed radiation side effects so far. - Denser treatment can potentially counteract resistance and "repopulation" of cancer cells between doses. AdvanCell therefore believes that future radioligand therapy perhaps should resemble more modern cancer treatment in general: 1. Hard induction phase for rapid tumor control 2. Then maintenance treatment to keep the disease down with lower burden They also use extensive PET/SPECT imaging and dosimetry to optimize the treatment.16 t sitten16 t sittenAdvanCell + Alpha-1 = first fully scalable Pb-212 treatment chain. Benefits for AdvanCell: • ✔ Isotope shortage eliminated • ✔ Dose intensity increases → better efficacy • ✔ FDA approval accelerated by 1–2 years • ✔ Phase 2 may be sufficient for approval • ✔ Indications may expand • ✔ Company value increases significantly New approval window for AdvanCell: 👉 2028–2030 (previously 2029–2031)
- ·2 päivää sittenDidn't see THAT coming!Poistettu·2 päivää sittenPoistettu·2 päivää sittenShorts trying their luck? They have increased somewhat lately and know that it can quickly go a bit sideways until after summer, just a thought. If one thinks long-term, just close Nordnet and open in autumn/possibly next year, then I believe one will be more than well in profit here. If one, however, is after quick money and trading, then this feels a bit dead now, at least until summer/August, but I can absolutely be wrong here. It just seems like we need some news, and even if everything is going smoothly, most is probably anticipated first after summer. But to put it in the drawer for half a year, probably absolutely fantastic. Only hope and belief, of course.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 058 | - | - | ||
| 1 | - | - | ||
| 12 | - | - | ||
| 14 | - | - | ||
| 570 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
2025 H2 -tulosraportti
78 päivää sitten
‧38 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 H1 -tulosraportti 28.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 H2 -tulosraportti 26.2. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2025 Q2 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenQube increases short https://investorprat.com/TRMED/short·3 t sittenexplains the significance of Qube's short in Thor Medical. With today's closing price of 4,43 kr, 0,8 % short corresponds to only around 2,9 million shares or approx. 13 million kroner. For a fund with enormous sums under management, this is in practice a very small position — approximately 0,003 % of a capital base of 380 billion NOK. I therefore believe this looks much more like regular algorithm/quant trading than a large fundamental bet against Thor Medical. Small and volatile biotech companies often automatically end up in such models due to liquidity, volatility, and issuance history. In my opinion, the size of the short at least does not indicate any strong conviction that the case will fail.
- ·1 päivä sittenThis is a stock for those with nerves of steel and a long-term perspective. During the recently held Mineral Days, the proximity and connection to Fensfeltet at Ulefoss (3.5 mil away) was emphasized as a strength for a long-term collaboration. Read the article here: https://www.linkedin.com/posts/thor-medical-asa_radioligandtherapy-nuclearmedicine-precisionmedicine-activity-7460210978530594816-w90h?utm_source=share&utm_medium=member_ios&rcm=ACoAAAcE6pMBR73kbdP4i1PKMH6bpO8f-HYw9-8
- 1 päivä sitten1 päivä sitten·1 päivä sittenAnna Karmann from AdvanCell gave a very interesting presentation at the UCSF-UCLA PSMA conference about something that may have been underestimated in radioligand therapy: dose optimization. Her main point was that today's approved RLT treatments like Lutathera and Pluvicto were developed extremely quickly, but without dose, treatment interval, and treatment duration being thoroughly optimized first. AdvanCell has therefore built dose optimization directly into the development of 212Pb-ADVC001, their lead-212-based PSMA alpha-therapy. The most interesting from the Phase 1 data: - The most intensive dosing regimens yielded the fastest and deepest PSA responses. - No dose-limiting toxicities were observed. - No dose reductions or severe delayed radiation side effects so far. - Denser treatment can potentially counteract resistance and "repopulation" of cancer cells between doses. AdvanCell therefore believes that future radioligand therapy perhaps should resemble more modern cancer treatment in general: 1. Hard induction phase for rapid tumor control 2. Then maintenance treatment to keep the disease down with lower burden They also use extensive PET/SPECT imaging and dosimetry to optimize the treatment.16 t sitten16 t sittenAdvanCell + Alpha-1 = first fully scalable Pb-212 treatment chain. Benefits for AdvanCell: • ✔ Isotope shortage eliminated • ✔ Dose intensity increases → better efficacy • ✔ FDA approval accelerated by 1–2 years • ✔ Phase 2 may be sufficient for approval • ✔ Indications may expand • ✔ Company value increases significantly New approval window for AdvanCell: 👉 2028–2030 (previously 2029–2031)
- ·2 päivää sittenDidn't see THAT coming!Poistettu·2 päivää sittenPoistettu·2 päivää sittenShorts trying their luck? They have increased somewhat lately and know that it can quickly go a bit sideways until after summer, just a thought. If one thinks long-term, just close Nordnet and open in autumn/possibly next year, then I believe one will be more than well in profit here. If one, however, is after quick money and trading, then this feels a bit dead now, at least until summer/August, but I can absolutely be wrong here. It just seems like we need some news, and even if everything is going smoothly, most is probably anticipated first after summer. But to put it in the drawer for half a year, probably absolutely fantastic. Only hope and belief, of course.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 058 | - | - | ||
| 1 | - | - | ||
| 12 | - | - | ||
| 14 | - | - | ||
| 570 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt